Remission and Mood in Response to severe asthma biologics

  • Research type

    Research Study

  • Full title

    What is the relationship between clinic remission and patient reported remission, and can either be predicted by mood?

  • IRAS ID

    325486

  • Contact name

    Matthew Masoli

  • Contact email

    matthew.masoli@nhs.net

  • Sponsor organisation

    Royal Devon University Healthcare NHS Foundation Trust

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    There are now 7 different biologic treatments available on the NHS in the UK. These treatments have dramatically changed how severe asthma can be treated with many patients, but not all, experiencing benefits from these drugs. Some patients experience far greater benefit than others to the point where they are said to be “in remission while on treatment”. Judgement on if “remission” has been achieved is currently made using a measure of symptoms (Asthma Control Questionnaire score), markers of inflammation (blood eosinophils and and lung function tests. In this study, we will investigate how patient perceptions of response to biologic drugs for severe asthma compare to this clinically led judgement.
    There is some data from rheumatoid arthritis and severe asthma that depression and/or anxiety decreases the benefit patients get from their biologic treatments, and potentially increase the time to experience the first benefits. Therefore, we will also look at whether a patent’s ability to achieve “remission” is related to positive and/or negative mood.

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    24/PR/0792

  • Date of REC Opinion

    1 Aug 2024

  • REC opinion

    Further Information Favourable Opinion